Pentagon and HHS Clear Emergency Path for Ketamine Painkiller Linked to $41 Million No-Bid Contract

Two signatures, one Federal Register notice, zero public explanation

On July 15, 2026, Defense Secretary Pete Hegseth determined that a military emergency, or a significant potential for one, existed involving heightened risk to U.S. forces from chemical, biological, radiological, or nuclear attack, as well as conventional weapons, according to Global Biodefense. On August 31, HHS Secretary Robert F. Kennedy Jr. followed with his own declaration, finding circumstances existed to justify emergency use authorizations for drugs treating moderate-to-severe acute pain in military casualties.

The combined notice landed in the Federal Register on September 3. It didn't name a drug, a company, or a specific threat. It just opened a legal door.

That door runs through Section 564 of the Food, Drug, and Cosmetic Act, which lets HHS trigger emergency use authorizations off four possible determinations: a Homeland Security domestic emergency, a material threat finding, an HHS public health emergency, or a Defense Department military emergency. This one used the military-emergency trigger, a path Global Biodefense notes is far less common than the pandemic-era EUAs most Americans remember. The declaration itself doesn't authorize any product. It just clears the way for the FDA Commissioner to approve specific ones the Pentagon backs.

The company that showed up days later

A few days after the notice posted, Singapore-based iX Biopharma put out a press release announcing the U.S. government had cleared an emergency use pathway for its sublingual ketamine product, Wafermine, according to MedPage Today.

iX Biopharma isn't a stranger to the Pentagon. Earlier in 2026 the company landed a $41 million sole-source contract from the Trump Defense Department to develop the compound, funding in part a phase III trial that MedPage Today reports is still underway. An unnamed source described the arrangement to MedPage Today as "bizarre." Military sources told the outlet the contract is structured as an Other Transaction Agreement, a mechanism that gives commanders flexibility but sits outside the competitive bidding rules federal law otherwise favors.

Terry Adirim, MD, a former acting assistant secretary of defense for health affairs, told MedPage Today the arrangement "deserve[s] transparency and scrutiny." She questioned why a still-unapproved formulation needs to jump an emergency pathway before its phase III studies and normal FDA review are finished, and said she'd want to see the government's justification for the no-bid deal. HHS did not respond to MedPage Today's request for comment.

The case for moving fast

Adirim didn't dismiss the idea outright. She noted sublingual ketamine is "easy to carry, and needle-free for use in large-scale combat," a real advantage in a mass-casualty scenario where medics can't reliably start an IV. Ketamine already has a long battlefield track record: military guidelines currently recommend its intravenous, intramuscular, and intranasal forms for significant combat pain, according to MedPage Today, in part because it causes less respiratory depression and less blood-pressure drop than opioids, which matters for casualties in shock or hemorrhaging.

So the operational logic isn't crazy on its face. A needle-free version that dissolves under the tongue could matter in a chemical or radiological attack where medics are overwhelmed and IV access is a luxury. Adirim's point isn't that the drug is a bad idea. It's that the government hasn't explained, on the record, why this specific product needed a no-bid contract and an emergency legal shortcut instead of the normal process.

What's still unknown

It isn't clear from the Federal Register notice whether the emergency declaration applies only to Wafermine or could cover other pain drugs the Pentagon identifies later, since individual authorizations get published separately, per Global Biodefense. Adirim also raised the question of whether the underlying threat determination connects to a potential escalation involving Iran, a link Global Biodefense's headline frames as "amid ongoing Iran conflict" but which neither source confirms with an on-record government statement.

Separately, and unrelated to the Pentagon action, ketamine's footprint in military-adjacent health care is expanding on another front. Bloom Integrated Health in Tampa Bay announced August 28 that it now accepts TRICARE for eligible mental-health services, including individualized plans that may incorporate self-pay ketamine for PTSD, according to an ACCESS Newswire release from the company. TRICARE doesn't cover the ketamine itself, which the release says generally costs under $20, only the surrounding evaluations and therapy. Ketamine remains off-label for PTSD, not FDA-approved for any psychiatric use, and that program has no connection to the Wafermine contract or the emergency declaration.

The question remains whether the Pentagon or HHS will release the justification for the sole-source award and the emergency pathway, or whether the first specific EUA for the drug will arrive, as the framework allows, without one.